Drug companies are expected to do well under Medicare Part D, but not this well.
Prescription tracking data from outfits like IMS Health have shown a disproportionate increase in volume since the start of the...
Part D Muddies Script Counts
Prescription tracking data from companies like IMS Health have shown a disproportionate increase in volume since the start of the Part D benefit in January, according to an analysis by Prudential Securities analyst Tim Anderson. One reason is in the way the Medicare drug benefit appears to increase the number of new prescriptions for brands.
More from Market Access
More from Pink Sheet
• By
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
• By
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
• By
The European Medicines Agency has recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy, despite the product securing approvals in the US and other markets.